General Information of Drug Off-Target (DOT) (ID: OTATVST8)

DOT Name SLAM family member 8 (SLAMF8)
Synonyms B-lymphocyte activator macrophage expressed; BCM-like membrane protein; CD antigen CD353
Gene Name SLAMF8
Related Disease
Advanced cancer ( )
Glioma ( )
Immune system disorder ( )
Inflammatory bowel disease ( )
Mastocytosis ( )
Hepatitis ( )
Crohn disease ( )
UniProt ID
SLAF8_HUMAN
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Sequence
MVMRPLWSLLLWEALLPITVTGAQVLSKVGGSVLLVAARPPGFQVREAIWRSLWPSEELL
ATFFRGSLETLYHSRFLGRAQLHSNLSLELGPLESGDSGNFSVLMVDTRGQPWTQTLQLK
VYDAVPRPVVQVFIAVERDAQPSKTCQVFLSCWAPNISEITYSWRRETTMDFGMEPHSLF
TDGQVLSISLGPGDRDVAYSCIVSNPVSWDLATVTPWDSCHHEAAPGKASYKDVLLVVVP
VSLLLMLVTLFSAWHWCPCSGKKKKDVHADRVGPETENPLVQDLP
Function May play a role in B-lineage commitment and/or modulation of signaling through the B-cell receptor.
Tissue Specificity Expressed in lymph node, spleen, thymus and bone marrow.

Molecular Interaction Atlas (MIA) of This DOT

7 Disease(s) Related to This DOT
Disease Name Disease ID Evidence Level Mode of Inheritance REF
Advanced cancer DISAT1Z9 Strong Biomarker [1]
Glioma DIS5RPEH Strong Biomarker [1]
Immune system disorder DISAEGPH Strong Biomarker [1]
Inflammatory bowel disease DISGN23E Strong Biomarker [2]
Mastocytosis DIS1TEE0 Strong Altered Expression [3]
Hepatitis DISXXX35 Disputed Biomarker [4]
Crohn disease DIS2C5Q8 Limited Genetic Variation [2]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 Disease(s)
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DOT
4 Drug(s) Affected the Gene/Protein Processing of This DOT
Drug Name Drug ID Highest Status Interaction REF
Tretinoin DM49DUI Approved Tretinoin increases the expression of SLAM family member 8 (SLAMF8). [5]
Calcitriol DM8ZVJ7 Approved Calcitriol decreases the expression of SLAM family member 8 (SLAMF8). [6]
DNCB DMDTVYC Phase 2 DNCB decreases the expression of SLAM family member 8 (SLAMF8). [7]
Benzo(a)pyrene DMN7J43 Phase 1 Benzo(a)pyrene decreases the expression of SLAM family member 8 (SLAMF8). [8]
------------------------------------------------------------------------------------
1 Drug(s) Affected the Post-Translational Modifications of This DOT
Drug Name Drug ID Highest Status Interaction REF
Bisphenol A DM2ZLD7 Investigative Bisphenol A decreases the methylation of SLAM family member 8 (SLAMF8). [9]
------------------------------------------------------------------------------------

References

1 Costimulatory checkpoint SLAMF8 is an independent prognosis factor in glioma.CNS Neurosci Ther. 2019 Mar;25(3):333-342. doi: 10.1111/cns.13041. Epub 2018 Aug 13.
2 Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease.Nat Genet. 2017 Feb;49(2):256-261. doi: 10.1038/ng.3760. Epub 2017 Jan 9.
3 SLAM family member 8 is involved in oncogenic KIT-mediated signalling in human mastocytosis.Exp Dermatol. 2018 Jun;27(6):641-646. doi: 10.1111/exd.13523.
4 Combined deficiency of SLAMF8 and SLAMF9 prevents endotoxin-induced liver inflammation by downregulating TLR4 expression on macrophages.Cell Mol Immunol. 2020 Feb;17(2):153-162. doi: 10.1038/s41423-018-0191-z. Epub 2018 Dec 14.
5 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
6 Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
7 Microarray analyses in dendritic cells reveal potential biomarkers for chemical-induced skin sensitization. Mol Immunol. 2007 May;44(12):3222-33.
8 Transcriptional signature of human macrophages exposed to the environmental contaminant benzo(a)pyrene. Toxicol Sci. 2010 Apr;114(2):247-59.
9 DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.